Literature DB >> 22999608

Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.

Jai G Parekh, T Hunter Newsom, Steven Nielsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22999608     DOI： 10.1016/j.jcrs.2012.08.032

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN： 0886-3350            Impact factor:   3.351


× No keyword cloud information.
  4 in total

1.  Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.

Authors:  Martin J Coffey; Heleen H Decory; Stephen S Lane
Journal:  Clin Ophthalmol       Date:  2013-02-13

2.  Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.

Authors:  Frank A Bucci; Ruth E Evans; Loretta M Amico; Timothy W Morris; Angel T Fluet; Christine M Sanfilippo; Heleen H DeCory; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2015-05-13

Review 3.  Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections.

Authors:  Francis S Mah; Christine M Sanfilippo
Journal:  Ophthalmol Ther       Date:  2016-03-24

4.  Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients.

Authors:  Steven A Nielsen; Marguerite B McDonald; Parag A Majmudar
Journal:  Clin Ophthalmol       Date:  2013-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.